查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010061

消化器官系統藥物市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、分子類型、劑型、適應症、最終用戶和分銷管道分類）

Gastrointestinal Drugs Market by Drug Class, Route Of Administration, Molecule Type, Formulation Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，胃腸道藥物市場價值為622.3億美元，預計到2026年將成長至654.5億美元，複合年成長率為5.45%，到2032年將達到902.6億美元。

主要市場統計數據
基準年 2025 622.3億美元
預計年份：2026年 654.5億美元
預測年份 2032 902.6億美元
複合年成長率 (%) 5.45%

對不斷發展的胃腸道治療生態系統進行策略性展望，概述臨床因素、醫療保健服務的變革、法規環境的變化以及以患者為中心的創新。

胃腸道治療市場正處於轉折點，其促進因素包括臨床因素、人口因素和技術因素。儘管慢性胃腸道疾病和急性症狀的治療仍然是產品需求的主要驅動力，但不斷發展的治療標準和患者期望正迫使製藥公司在作用機制、製劑和給藥方法方面進行創新。標靶小分子化合物、生物製藥支持策略以及以微生物組為中心的療法等新治療方法正在重新定義治療模式，並為臨床差異化開闢新的途徑。

重大的科學、監管和商業性變革正在透過微生物組科學、精準醫療和數位化醫療服務重塑胃腸道護理。

近年來，胃腸道疾病的認知、治療和管理方式發生了翻天覆地的變化。科學進步不再局限於緩解症狀，而是轉向干預潛在的病理生理機制，例如標靶藥物以影響胃酸分泌、腸道蠕動和黏膜發炎。同樣重要的是，微生物組科學作為一種潛在的治療方式正在崛起。調節微生物組和腸道屏障功能的干涉措施正從發現階段進入臨床試驗，這對傳統的藥物研發路徑提出了新的挑戰。

貿易政策和關稅措施的變化如何重塑消化器官系統藥物的供應鏈選擇、成本結構、籌資策略和市場定位。

關稅和貿易措施的推出可能會顯著改變消化器官系統藥品生產商和經銷商的成本結構、供應鏈設計和採購決策。進口活性藥物原料藥和成品的關稅提高會立即對投入成本造成壓力，迫使企業重新評估與供應商的關係、合約條款和庫存策略。為了因應這種情況，企業通常會尋求生產近岸外包、擴大雙重採購策略，並加強與合約開發和生產合作夥伴的合作，以維持獲利能力和供應的連續性。

將治療領域、給藥途徑、臨床適應症和通路聯繫起來的詳細細分見解，有助於制定研發重點和商業化策略。

了解市場區隔趨勢對於確定研發重點、通路策略和臨床定位至關重要。在藥物類別中，制酸劑在症狀治療中發揮基礎作用，其活性成分各不相同，例如氫氧化鋁、碳酸鈣、氫氧化鎂和碳酸氫鈉。每種制酸劑的耐受性、起效時間和給藥途徑各不相同，這影響了它們作為處方藥和非處方藥的定位。止瀉藥，包括次水楊酸鉍和洛哌丁胺等化合物，繼續滿足急性治療需求，並在間歇性治療策略中發揮關鍵作用。解痙藥，包括二環己胺和莨菪鹼等藥物，用於治療功能障礙，通常與飲食和行為療法聯合用於多方面治療方法中。瀉藥和質子幫浦阻斷劑作為補充治療選擇，需要針對安全性、長期使用效果和患者依從性進行差異化訊息。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和獨特的醫療保健生態系統正在推動獨特的監管、製造和商業策略。

區域趨勢差異顯著，直接影響監管策略、供應鏈結構和商業性實施。在美洲，循證報銷和支付方主導的成本控制備受重視，並由此塑造了產品定位。先進的診斷技術在門診和住院環境中都為展現產品價值提供了重要機會。研究、臨床試驗基礎設施和成熟的分銷網路促進了差異化治療方法的快速商業化，而政策變化和對定價的嚴格審查則要求構建清晰的衛生經濟學論點。

不同的競爭原型、策略聯盟和能力主導的差異化如何塑造消化器官系統療法的企業策略和商業性成果。

消化器官系統藥物市場的競爭格局呈現出多元化的特點，既有老牌製藥公司，也有靈活敏捷的專業生物技術公司、非專利藥生產商和契約製造組織（CMO）。老牌品牌藥生產商憑藉豐富的臨床數據、與處方醫生建立的穩固關係以及整合的銷售團隊來維持其市場地位，而專業生物技術公司則透過探索新的作用機制和特定適應症來脫穎而出。學名藥和商品化產品在市場准入和銷售量方面仍然佔據重要地位，其價格壓力影響著毛利率策略和產品生命週期延長策略。

為產業領導者提供切實可行的策略重點和營運干預措施，以增強韌性、加速創新並展現永續的治療價值。

產業領導者應優先採取一系列策略行動，以因應科學的複雜性、供應鏈的波動性和支付者的需求。首先，應投資於供應鏈多元化和韌性，具體措施包括發展二級供應商、加強與契約製造製造商的關係以及評估區域製造地，以降低關稅和物流風險。將情境規劃融入採購和供應策略，可以降低政策突變的風險，並保障病人獲得醫療服務。

採用嚴謹的混合方法研究方法，結合專家的初步訪談、全面的二次分析、檢驗和品質保證，以檢驗實務見解。

本研究途徑結合了結構化的專家訪談、對臨床、監管和商業文獻的詳細二次分析以及系統性的整合，從而確保了研究結果的可靠性。主要研究包括對臨床醫生、供應鏈專家、監管人員和銷售主管的定性訪談，旨在捕捉治療方法採納、處方集趨勢和營運限制等方面的細微觀點。基於這些第一手信息，研究人員對臨床實踐模式和商業策略進行了解讀，並與同行評審文獻和監管指導文件進行了交叉比對。

整合臨床、商業性和營運方面的挑戰，以確定胃腸道治療領域持續成功的核心優先事項。

總之，消化器官系統療法的市場格局正受到科學創新、變革性醫療服務模式以及貿易政策和支付方審查等外部壓力的重塑。新治療方法、以微生物組為中心的研究以及數位健康能力的相互作用，既為研發團隊和商業團隊帶來了機遇，也帶來了挑戰。同時，供應鏈韌性和關稅考量已成為營運規劃中不可或缺的要素，影響採購決策和定價策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：消化器官系統市場：依藥物類別分類

  • 制酸劑
    • 氫氧化鋁
    • 碳酸鈣
    • 氫氧化鎂
    • 碳酸氫鈉
  • 止瀉藥
    • 次水楊酸鉍
    • 洛哌丁胺
  • 解痙藥
    • 二環胺
    • 莨菪鹼
  • 瀉藥
  • 質子幫浦阻斷劑
    • 奧美拉唑
    • Esomeprazole
    • 蘭索拉唑
    • Rabeprazole
  • 運動興奮劑
    • 多巴胺拮抗劑
    • 血清素 5-HT4 受體促效劑
    • 大環內酯類運動興奮劑
  • 止吐藥
    • Ondansetron
    • 丙氯拉嗪

第9章：消化器官系統藥物市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
  • 口服
    • 膠囊
      • 硬殼
      • 軟凝膠
    • 粉末
    • 藥片
  • 直腸

第10章：以分子類型分類的消化器官系統藥物市場

  • 低分子
  • 生物製藥
  • 生物相似藥
  • 胜肽
  • 酵素替代療法
  • 重組蛋白
  • 生物療法製劑

第11章：以劑型分類的消化器官系統藥物市場

  • 速釋製劑
  • 緩釋製劑
  • 腸溶製劑
  • 固定劑量組合藥物
  • 液體

第12章：消化器官系統藥物市場：依適應症分類

  • 便秘
  • 胃食道逆流症
  • 腹瀉
  • 大腸激躁症
  • 消化性潰瘍
  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 胃輕癱

第13章：消化器官系統藥物市場：依最終用戶分類

  • 診所
    • 胃腸病診所
    • 一般診所
  • 家庭醫療保健
  • 醫院

第14章：消化器官系統藥物市場：依分銷管道分類

  • 離線
    • 醫院藥房
    • 零售藥房
    • 專科藥房
  • 網路藥房

第15章：消化器官系統藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：消化器官系統藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：消化器官系統藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國消化器官系統藥物市場

第19章：中國消化器官系統藥物市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Limited
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Reckitt Benckiser Group plc
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA051D0

The Gastrointestinal Drugs Market was valued at USD 62.23 billion in 2025 and is projected to grow to USD 65.45 billion in 2026, with a CAGR of 5.45%, reaching USD 90.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 62.23 billion
Estimated Year [2026] USD 65.45 billion
Forecast Year [2032] USD 90.26 billion
CAGR (%) 5.45%

A strategic orientation to the evolving gastrointestinal therapeutic ecosystem that outlines clinical drivers, care delivery shifts, regulatory inflections, and patient-centered innovation

The gastrointestinal therapeutics landscape is at an inflection point driven by converging clinical, demographic, and technological forces. Chronic gastrointestinal disorders and acute symptom management continue to shape product demand, while evolving standards of care and patient expectations pressure manufacturers to innovate across mechanism of action, formulation, and delivery. Newer therapeutic modalities, including targeted small molecules, biologic-supporting strategies, and microbiome-centered approaches, are redefining treatment paradigms and creating novel pathways for clinical differentiation.

Alongside therapeutic innovation, healthcare delivery transformation-characterized by greater outpatient care, telehealth adoption, and personalized medicine initiatives-has shifted how patients access and adhere to treatments. Regulatory environments are adapting to expedited pathways and real-world evidence requirements, prompting companies to rethink development plans and post-market evidence generation. Meanwhile, cost containment and payer scrutiny remain persistent constraints that require careful commercial planning and evidence-based value propositions.

Taken together, these dynamics demand an integrated approach that synthesizes clinical insight, patient-centric product design, and supply chain resilience. This introduction frames the principal forces shaping gastrointestinal drug development and commercialization, setting the stage for deeper analysis into transformative shifts, tariff implications, segmentation performance, regional nuances, and recommended actions for stakeholders seeking to sustain competitive advantage.

Pivotal scientific, regulatory, and commercial transformations reshaping gastrointestinal therapeutics through microbiome science, precision approaches, and digital-enabled care delivery

Recent years have produced transformative shifts that are redefining how gastrointestinal disorders are understood, treated, and managed. Scientific advances have expanded beyond symptomatic relief toward interventions that modify underlying pathophysiology, including targeted agents that influence acid secretion, gut motility, and mucosal inflammation. Equally important is the emergence of microbiome science as a potential therapeutic lever; interventions that modulate microbial communities and intestinal barrier function are moving from discovery into clinical experimentation, challenging conventional drug development pathways.

Concurrently, precision approaches are gaining traction, supported by biomarker development, diagnostic refinement, and risk stratification tools that enable more tailored therapy selection. Digital health innovations that monitor symptoms, adherence, and real-world outcomes are proving complementary to pharmacological interventions and are increasingly incorporated into development programs and post-market strategies. Formulation technology is also evolving, with controlled-release systems, softgel capsules, and alternative routes of administration improving tolerability and adherence.

From a commercial perspective, consolidation and partnerships between specialty biotech and traditional pharmaceutical companies are accelerating knowledge transfer and enabling faster scale-up of novel modalities. Regulatory frameworks and payer expectations continue to adapt, creating both opportunities for accelerated access and the requirement for robust value demonstration. These combined shifts signal a landscape where scientific novelty, patient-centric delivery, and adaptive commercial models determine who wins and who falls behind.

How changes in trade policy and tariff measures reshape supply chain choices, cost structures, sourcing strategies, and commercial positioning across gastrointestinal therapeutics

The introduction of tariffs and trade measures can materially alter cost structures, supply-chain design, and sourcing decisions for gastrointestinal drug manufacturers and distributors. Increased duties on imported active pharmaceutical ingredients or finished dosage forms create immediate input-cost pressures that compel companies to re-evaluate supplier relationships, contract terms, and inventory strategies. In response, organizations often pursue nearshoring of production, expand dual-sourcing strategies, or intensify engagement with contract development and manufacturing partners to preserve margins and continuity of supply.

Tariff-driven cost pressures also have downstream commercial implications. Payers and procurement entities may intensify price negotiations or seek alternative therapeutics with favorable cost profiles, which in turn influences portfolio prioritization and lifecycle management decisions. Companies that proactively model tariff scenarios and embed contingency plans into procurement and pricing playbooks are better positioned to mitigate margin erosion. These measures include longer-term supply agreements, hedging strategies for raw material purchases, and investments in domestic manufacturing capacity where economically justified.

Regulatory compliance and customs complexity increase administrative burden, requiring closer coordination between regulatory, supply chain, and commercial teams. As a result, cross-functional planning becomes a competitive necessity rather than an operational nicety. Firms that combine agile sourcing, transparent supplier audits, and robust demand forecasting will navigate tariff volatility more successfully while maintaining patient access and service levels.

Deep segmentation insight linking therapeutic classes, delivery routes, clinical indications, and distribution pathways to inform R&D focus and commercialization strategies

Understanding segmentation dynamics is essential to prioritize R&D focus, channel strategies, and clinical positioning. Within drug class, antacids play a foundational role in symptomatic management and are differentiated by active agents such as aluminum hydroxide, calcium carbonate, magnesium hydroxide, and sodium bicarbonate, each with distinct tolerability, onset-of-action, and dosing profiles that inform formulary placement and over-the-counter positioning. Antidiarrheals, including compounds such as bismuth subsalicylate and loperamide, continue to serve acute care needs and remain important for episodic treatment strategies. Antispasmodics encompassing agents like dicyclomine and hyoscyamine address functional disorders and are frequently considered within multi-modal treatment regimens alongside dietary and behavioral interventions. Laxatives and proton pump inhibitors complete the therapeutic mix and require differentiated messaging around safety, chronic use implications, and patient adherence initiatives.

Route of administration distinctions influence clinical applicability and patient preference. Injectable forms, subdivided into intramuscular and intravenous modalities, are essential in acute care settings and hospital protocols, while oral administration, which spans capsules, powders, and tablets, remains the dominant outpatient delivery mode. Capsules themselves split into hard shell and soft gel formats, with soft gels often chosen for improved swallowing and bioavailability for certain actives. Topical approaches-delivered as creams, gels, or patches-offer localized symptom control and an alternative pathway for certain adjunctive treatments.

Indication-focused segmentation shapes clinical development and marketing priorities, with conditions such as constipation, diarrhea, gastroesophageal reflux disease, irritable bowel syndrome, and peptic ulcer disease each presenting unique efficacy, safety, and adherence challenges. Distribution channels alter access dynamics; brick-and-mortar pharmacies including hospital, retail, and specialty pharmacies remain critical for clinical settings while online pharmacies expand reach for chronic therapy and OTC sales. End users such as clinics-both gastroenterology and general practice-home healthcare environments, and hospitals require tailored engagement models, with clinics often influencing prescribing behavior and hospitals dictating inpatient formularies and acute care protocols.

Regional dynamics and differentiated healthcare ecosystems across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive distinct regulatory, manufacturing, and commercial strategies

Regional dynamics vary significantly and directly influence regulatory strategy, supply chain configuration, and commercial execution. In the Americas, a strong emphasis on evidence-based reimbursement and payer-driven cost containment shapes product positioning, with significant opportunities tied to advanced diagnostics and value demonstration in both outpatient and hospital settings. Research, clinical trial infrastructure, and established distribution networks facilitate faster commercialization for differentiated therapies, while policy shifts and pricing scrutiny necessitate clear health-economic narratives.

Europe, the Middle East & Africa presents a mosaic of regulatory approaches and market maturity levels. Western European markets often demand comprehensive clinical and economic evidence and operate within sophisticated reimbursement frameworks, whereas emerging markets in the region may prioritize affordability and supply chain reliability. Regulatory harmonization efforts and regional procurement mechanisms can influence launch sequencing and pricing strategies. Manufacturers must balance portfolio access across heterogeneous healthcare systems by adapting pricing, localization of manufacturing, and partnerships with regional distributors.

Asia-Pacific markets are characterized by rapid growth in healthcare spending, expanding access, and diverse adoption patterns of innovative therapies. Manufacturing hubs and contract development and manufacturing organizations provide opportunities for cost-efficient production, while regulatory modernization in several countries accelerates approval pathways for novel agents. Patient populations with differing epidemiology and health-seeking behaviors require nuanced clinical and commercial strategies to optimize market entry and scale.

How diverse competitive archetypes, strategic alliances, and capability-led differentiation are shaping company strategies and commercial outcomes in gastrointestinal therapeutics

Competitive dynamics in gastrointestinal therapeutics are defined by a mix of legacy pharmaceutical firms, nimble specialty biotechs, generic manufacturers, and contract manufacturing organizations. Incumbent brand manufacturers often leverage extensive clinical data, established prescriber relationships, and integrated commercial teams to defend market positions, while specialized biotech firms pursue novel mechanisms and niche indications to create differentiation. Generics and commoditized products remain important for access and volume, exerting pricing pressure that shapes gross margin strategies and lifecycle extension tactics.

Strategic partnerships, licensing agreements, and technology collaborations are common as companies seek to combine capabilities in drug discovery, formulation technology, and digital health. Contract development and manufacturing partners play a pivotal role in enabling rapid scale-up and hedging supply risk, particularly for companies transitioning from early clinical proof-of-concept to commercial manufacturing. Business models that integrate real-world evidence platforms, patient support services, and digital adherence tools can strengthen therapeutic value propositions and support payer negotiations.

Successful companies increasingly adopt a portfolio approach that balances short-term revenue from established products with longer-term investment in innovative modalities. Emphasis on regulatory strategy, health economics, and targeted commercialization plans separates leaders who secure premium positioning from those who compete primarily on price.

Practical strategic priorities and operational interventions for industry leaders to strengthen resilience, accelerate innovation, and demonstrate sustained therapeutic value

Industry leaders should prioritize a set of strategic actions to navigate scientific complexity, supply-chain volatility, and payer demands. First, invest in supply chain diversification and resilience by developing secondary sourcing, strengthening relationships with contract manufacturers, and evaluating regional manufacturing footprints to mitigate tariff and logistics risk. Embedding scenario planning into procurement and supply strategies reduces exposure to abrupt policy changes and preserves patient access.

Second, accelerate capability building in microbiome research, biomarker development, and formulation science to capture emerging therapeutic opportunities. Supporting translational research and adaptive clinical designs will shorten development timelines and improve the likelihood of clinical differentiation. Third, integrate digital health and real-world evidence platforms into development and commercialization plans to support adherence, monitor outcomes, and substantiate value for payers and providers.

Fourth, tailor commercial models to distribution and end-user characteristics, aligning messaging and service offerings with the needs of hospitals, gastroenterology clinics, general practice clinics, and home healthcare providers. Finally, maintain active regulatory engagement and robust health-economic modeling to anticipate reimbursement trajectories and demonstrate value across diverse regional systems. These combined actions create a pragmatic roadmap for sustaining competitiveness and driving long-term growth.

A rigorous mixed-methods research approach combining expert primary engagement, comprehensive secondary analysis, triangulation, and quality assurance to validate actionable insights

The research approach combines structured primary engagement with domain experts, in-depth secondary analysis of clinical, regulatory, and commercial literature, and systematic synthesis to ensure credible insights. Primary research included qualitative interviews with clinicians, supply chain specialists, regulatory affairs leaders, and commercial executives to capture nuanced perspectives on therapeutic adoption, formulary dynamics, and operational constraints. These firsthand accounts informed interpretation of clinical practice patterns and commercial strategies, and were triangulated against peer-reviewed literature and regulatory guidance documents.

Secondary research encompassed analysis of scientific publications, clinical trial registries, regulatory notices, and public company disclosures to map innovation trends, safety considerations, and development pipelines. Synthesis involved cross-validating themes across data sources, identifying convergent trends, and highlighting areas of discrepancy that warrant further investigation. Limitations include variance in public reporting across regions and the evolving nature of clinical evidence for novel modalities. To mitigate these constraints, findings emphasize robust patterns and practitioner-validated insights rather than speculative projections.

Quality assurance comprised peer review by therapeutic area experts, methodological checks on source credibility, and iterative refinement of conclusions based on stakeholder feedback. This layered methodology supports a reliable foundation for strategic decision-making while acknowledging the dynamic context of gastrointestinal therapeutics.

Synthesis of clinical, commercial, and operational imperatives that identify the core priorities for sustained success in gastrointestinal therapeutics moving forward

In conclusion, the gastrointestinal therapeutics landscape is being reshaped by scientific innovation, shifts in care delivery, and external pressures such as trade policy and payer scrutiny. The interplay of new therapeutic modalities, microbiome-focused research, and digital health capabilities creates both opportunity and complexity for developers and commercial teams. At the same time, supply-chain resilience and tariff awareness have become essential components of operational planning, influencing sourcing decisions and pricing strategies.

Segmentation clarity-across drug classes, routes of administration, clinical indications, distribution channels, and end users-remains critical to prioritize investment and craft targeted value propositions. Regional heterogeneity further necessitates adaptable regulatory and commercialization plans that reflect distinct payer expectations and healthcare infrastructure. Companies that combine scientific rigor with pragmatic supply-chain planning, integrated digital strategies, and strong payer engagement will be best positioned to deliver differentiated therapies that meet clinical needs while achieving sustainable commercial returns.

The path forward favors organizations that embrace cross-functional collaboration, invest in translational science, and maintain agility in the face of policy and market shifts. By aligning development priorities with real-world care delivery demands and operational resilience, stakeholders can capture emerging opportunities while safeguarding patient access and therapeutic continuity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Drugs Market, by Drug Class

  • 8.1. Antacids
    • 8.1.1. Aluminum Hydroxide
    • 8.1.2. Calcium Carbonate
    • 8.1.3. Magnesium Hydroxide
    • 8.1.4. Sodium Bicarbonate
  • 8.2. Antidiarrheals
    • 8.2.1. Bismuth Subsalicylate
    • 8.2.2. Loperamide
  • 8.3. Antispasmodics
    • 8.3.1. Dicyclomine
    • 8.3.2. Hyoscyamine
  • 8.4. Laxatives
  • 8.5. Proton Pump Inhibitors
    • 8.5.1. Omeprazole
    • 8.5.2. Esomeprazole
    • 8.5.3. Lansoprazole
    • 8.5.4. Rabeprazole
  • 8.6. Prokinetics
    • 8.6.1. Dopamine Antagonists
    • 8.6.2. Serotonin 5-HT4 Agonists
    • 8.6.3. Macrolide Prokinetics
  • 8.7. Antiemetics
    • 8.7.1. Ondansetron
    • 8.7.2. Prochlorperazine

9. Gastrointestinal Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
  • 9.2. Oral
    • 9.2.1. Capsules
      • 9.2.1.1. Hard Shell
      • 9.2.1.2. Soft Gel
    • 9.2.2. Powders
    • 9.2.3. Tablets
  • 9.3. Rectal

10. Gastrointestinal Drugs Market, by Molecule Type

  • 10.1. Small Molecule
  • 10.2. Biologic
  • 10.3. Biosimilar
  • 10.4. Peptide
  • 10.5. Enzyme Replacement
  • 10.6. Recombinant Protein
  • 10.7. Live Biotherapeutic

11. Gastrointestinal Drugs Market, by Formulation Type

  • 11.1. Immediate Release
  • 11.2. Extended Release
  • 11.3. Enteric Coated
  • 11.4. Fixed Dose Combination
  • 11.5. Liquid Formulation

12. Gastrointestinal Drugs Market, by Indication

  • 12.1. Constipation
  • 12.2. Gastroesophageal Reflux Disease
  • 12.3. Diarrhea
  • 12.4. Irritable Bowel Syndrome
  • 12.5. Peptic Ulcer Disease
  • 12.6. Inflammatory Bowel Disease
    • 12.6.1. Crohn's Disease
    • 12.6.2. Ulcerative Colitis
  • 12.7. Gastroparesis

13. Gastrointestinal Drugs Market, by End User

  • 13.1. Clinics
    • 13.1.1. Gastroenterology Clinics
    • 13.1.2. General Practice Clinics
  • 13.2. Home Healthcare
  • 13.3. Hospitals

14. Gastrointestinal Drugs Market, by Distribution Channel

  • 14.1. Offline
    • 14.1.1. Hospital Pharmacies
    • 14.1.2. Retail Pharmacies
    • 14.1.3. Specialty Pharmacies
  • 14.2. Online Pharmacies

15. Gastrointestinal Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Gastrointestinal Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Gastrointestinal Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Gastrointestinal Drugs Market

19. China Gastrointestinal Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Amgen Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Bausch Health Companies Inc.
  • 20.9. Bayer AG
  • 20.10. Boehringer Ingelheim International GmbH
  • 20.11. Bristol-Myers Squibb
  • 20.12. Cipla Limited
  • 20.13. Cosmo Pharmaceuticals N.V.
  • 20.14. Dr. Reddy's Laboratories Ltd.
  • 20.15. Eli Lilly and Company
  • 20.16. F. Hoffmann-La Roche Ltd
  • 20.17. Ferring International Center S.A.
  • 20.18. GlaxoSmithKline plc
  • 20.19. Ironwood Pharmaceuticals, Inc.
  • 20.20. Johnson & Johnson Services, Inc.
  • 20.21. Merck & Co., Inc.
  • 20.22. Novartis AG
  • 20.23. Otsuka Pharmaceutical Co., Ltd.
  • 20.24. Pfizer Inc.
  • 20.25. Reckitt Benckiser Group plc
  • 20.26. Sanofi S.A.
  • 20.27. Takeda Pharmaceutical Company Limited
  • 20.28. Teva Pharmaceutical Industries Ltd.
  • 20.29. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CALCIUM CARBONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CALCIUM CARBONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SODIUM BICARBONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SODIUM BICARBONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LOPERAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LOPERAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LOPERAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DICYCLOMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DICYCLOMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DICYCLOMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HYOSCYAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HYOSCYAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HYOSCYAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SEROTONIN 5-HT4 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SEROTONIN 5-HT4 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SEROTONIN 5-HT4 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MACROLIDE PROKINETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MACROLIDE PROKINETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MACROLIDE PROKINETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HARD SHELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HARD SHELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HARD SHELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SOFT GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SOFT GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SOFT GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENZYME REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENZYME REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENZYME REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIVE BIOTHERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIVE BIOTHERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIVE BIOTHERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENTERIC COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENTERIC COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ENTERIC COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CONSTIPATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CONSTIPATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CONSTIPATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DIARRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROPARESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROPARESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIDIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTISPASMODICS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY PROKINETICS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPE GASTROINTESTINAL DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILL